“Meso-tetra (4-carboMeso-tetra (4-carboxyphenyl) porphyrin (TCPP) is taken up in cancer cells by the CD320 receptor” at the International Conference on Porphyrins and Phthalocyanines (ICPP) ICPP-11, June 26 through July 2, 2021

PUBLISHED ON June 22, 2021

The poster presents the novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells. These discoveries have furthered our understanding of TCPP for use in diagnostics including the Company’s first product, CyPath® Lung, a flow cytometry test used to diagnose lung cancer at early stage.

read more

“Selective Cancer Cell Killing by Dual siRNA Knockdown of CD320 and LRP2 Receptors” RNA Therapeutics Institute’s 2021 RNA Therapeutics Symposium at the University of Massachusetts Medical School June 23 – 25, 2021

PUBLISHED ON June 22, 2021

The presentation explains bioAffinity Technologies’ discovery of a fundamental vulnerability of cancer opens the way to new therapies that kill cancer without harm to normal tissue. In particular, bioAffinity’s research shows how the Company has designed and used siRNAs to kill multiple cancers at the cellular level including prostate, lung, breast, brain and skin cancers without harm to normal cells.

read more

“Simultaneous knockdown of CD320 and LRP2 receptors is selectively toxic to cancer cells but not normal cells,” American Association of Cancer Research (AACR) Annual Meeting 2021, April-May, 2021

PUBLISHED ON May 22, 2021

The presentation reports on research leading to selective killing of cancer cells without harm to normal cells. During efforts to elucidate the mechanism by which TCPP selectively accumulates in cancer cells, we discovered that simultaneous knock down of two LDLR-family receptors was selectively cytotoxic to cancer cells and not to normal cells.

read more

Identification of a novel mechanism for meso‐tetra (4‐carboxyphenyl) porphyrin (TCPP) uptake in cancer cells, Journal of the Federation of Societies for the Study of Experimental Biology (FASEB Journal), Feb. 25, 2021

PUBLISHED ON April 20, 2021

The paper explains research that identified a novel mechanism by which the porphyrin TCPP, which is used in bioAffinity Technologies’ non-invasive test for the early detection of lung cancer, is incorporated into cancer cells using the cellular receptor CD320, which is involved in the uptake of Vitamin B12.

read more

bioAffinity Technologies was selected as one of San Antonio’s Top 2020 Innovators. In this video, you will see Maria Zannes, President and Chief Executive Officer, speak about what drives motivation, innovation and success and kick off San Antonio’s premier annual event celebrating the City’s healthcare and bioscience industry.

 

www.thehealthcell.org/sitepage/state-of-the-industry/